Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 184

1.

Natural antibodies to oxidation-specific epitopes: Innate immune response and venous thromboembolic disease.

Eichinger S, Kyrle PA, Kammer M, Eischer L, Ozsvar Kozma M, Binder CJ.

J Thromb Haemost. 2017 Oct 17. doi: 10.1111/jth.13874. [Epub ahead of print]

PMID:
29045005
2.

Disease prevalence dependent failure rate in diagnostic management studies on suspected deep vein thrombosis: communication from the SSC of the ISTH.

Dronkers CEA, Ende-Verhaar YM, Kyrle PA, Righini M, Cannegieter SC, Huisman MV, Klok FA; Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.

J Thromb Haemost. 2017 Aug 20. doi: 10.1111/jth.13805. [Epub ahead of print] No abstract available.

PMID:
28922557
3.

Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.

Eischer L, Kammer M, Traby L, Kyrle PA, Eichinger S.

J Thromb Haemost. 2017 Jul;15(7):1368-1374. doi: 10.1111/jth.13702. Epub 2017 May 18.

PMID:
28407356
4.

Towards a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: communication from the SSC of the ISTH.

Dronkers CEA, van der Hulle T, Le Gal G, Kyrle PA, Huisman MV, Cannegieter SC, Klok FA; Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.

J Thromb Haemost. 2017 May;15(5):1040-1043. doi: 10.1111/jth.13654. Epub 2017 Mar 11. No abstract available.

PMID:
28296048
5.

The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.

Kyrle PA, Kammer M, Eischer L, Weltermann A, Minar E, Hirschl M, Heinze G, Eichinger S.

J Thromb Haemost. 2016 Dec;14(12):2402-2409. doi: 10.1111/jth.13524. Epub 2016 Nov 19.

PMID:
27696701
6.

Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH.

Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease.

J Thromb Haemost. 2016 Jul;14(7):1480-3. doi: 10.1111/jth.13336. Epub 2016 Jun 7. No abstract available.

PMID:
27428935
7.

The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study.

Weisshaar S, Litschauer B, Bucher S, Riesenhuber M, Kapiotis S, Kyrle PA, Wolzt M.

Medicine (Baltimore). 2016 Jul;95(27):e4145. doi: 10.1097/MD.0000000000004145.

8.

Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.

Traby L, Kollars M, Kaider A, Eichinger S, Wolzt M, Kyrle PA.

J Thromb Haemost. 2016 Feb;14(2):273-81. doi: 10.1111/jth.13216. Epub 2016 Jan 30.

PMID:
26663880
9.

How I treat recurrent deep-vein thrombosis.

Kyrle PA.

Blood. 2016 Feb 11;127(6):696-702. doi: 10.1182/blood-2015-09-671297. Epub 2015 Dec 11.

10.

Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts.

Roach RE, Lijfering WM, Tait RC, Baglin T, Kyrle PA, Cannegieter SC, Rosendaal FR.

J Thromb Haemost. 2015 Oct;13(10):1815-22. doi: 10.1111/jth.13116. Epub 2015 Sep 7.

11.

The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.

Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MN, Poon MC; Glanzmann Thrombasthenia Registry Investigators.

Haematologica. 2015 Aug;100(8):1031-7. doi: 10.3324/haematol.2014.121475. Epub 2015 May 22.

12.

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention.

Poon MC, d'Oiron R, Zotz RB, Bindslev N, Di Minno MN, Di Minno G; Glanzmann Thrombasthenia Registry Investigators.

Haematologica. 2015 Aug;100(8):1038-44. doi: 10.3324/haematol.2014.121384. Epub 2015 May 22.

13.

Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data.

Marcucci M, Iorio A, Douketis JD, Eichinger S, Tosetto A, Baglin T, Cushman M, Palareti G, Poli D, Tait RC, Kyrle PA.

J Thromb Haemost. 2015 May;13(5):775-81. doi: 10.1111/jth.12871. Epub 2015 Mar 12.

14.

Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.

Weisshaar S, Litschauer B, Gouya G, Mayer P, Smerda L, Kapiotis S, Kyrle PA, Eichinger S, Wolzt M.

J Thromb Haemost. 2014 Nov;12(11):1850-60. doi: 10.1111/jth.12726. Epub 2014 Oct 16.

15.

Dabigatran: patient management in specific clinical settings.

Kyrle PA, Binder K, Eichinger S, F├╝gger R, Gollackner B, Hiesmayr JM, Huber K, Lang W, Perger P, Quehenberger P, Roithinger FX, Schmaldienst S, Weltermann A, Domanovits H.

Wien Klin Wochenschr. 2014 Sep;126(17-18):503-8. doi: 10.1007/s00508-014-0581-x. Epub 2014 Aug 20.

16.

Predicting recurrent venous thromboembolism in cancer: is it possible?

Kyrle PA.

Thromb Res. 2014 May;133 Suppl 2:S17-22. doi: 10.1016/S0049-3848(14)50003-5. Review.

PMID:
24862139
17.

Comment on "Venous thrombosis: who should be screened for thrombophilia in 2014?" Author's reply.

Kyrle PA.

Pol Arch Med Wewn. 2014;124(4):216. No abstract available.

18.

The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study.

Eischer L, Eichinger S, Kyrle PA.

J Thromb Haemost. 2014 May;12(5):635-40. doi: 10.1111/jth.12528.

19.

Venous thrombosis: who should be screened for thrombophilia in 2014?

Kyrle PA.

Pol Arch Med Wewn. 2014;124(1-2):65-9. Epub 2013 Dec 23. Review.

20.

D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model.

Eichinger S, Heinze G, Kyrle PA.

J Am Heart Assoc. 2014 Jan 2;3(1):e000467. doi: 10.1161/JAHA.113.000467.

Supplemental Content

Loading ...
Support Center